Meeting
2017 ASCO Annual Meeting
Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.
Authors
Nicolas Marie Guibert
Dana-Farber Cancer Institute, Boston, MA
Nicolas Marie Guibert , Cloud Paweletz , Yuebi Hu , Nora B. Feeney , Vincent Plagnol , Valerie Poole , Greg Jones , Geoffrey R. Oxnard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11529)
DOI
10.1200/JCO.2017.35.15_suppl.11529
Abstract #
11529
Poster Bd #
229
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
First Author: Akito Hata
Poster
2021 ASCO Annual Meeting
Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP).
First Author: Pasi A. Janne
Poster
2020 ASCO Virtual Scientific Program
ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).
First Author: Ji-Youn Han
Poster
2018 ASCO Annual Meeting
Landscape of osimertinib resistant mutations between the two common subtypes of EGFR 19del or L858R in NSCLC.
First Author: Yan Zhang